IL95472A - A medicinal product containing sertraline for use in the treatment of chemical addictions - Google Patents

A medicinal product containing sertraline for use in the treatment of chemical addictions

Info

Publication number: IL95472A
Authority: IL; Israel
Prior art keywords: dependency; sertraline; chemical; pharmaceutical preparation; pharmaceutical composition
Prior art date: 1989-08-30

Application number

IL9547290A

Other languages

English (en)

Hebrew (he)

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-30

Filing date

1990-08-23

Publication date

1996-05-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23584453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL95472(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-08-23 Application filed by Pfizer filed Critical Pfizer

1996-05-14 Publication of IL95472A publication Critical patent/IL95472A/en

Links

239000000126 substance Substances 0.000 title claims abstract description 17
229960002073 sertraline Drugs 0.000 title abstract description 13
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title abstract description 13
239000008194 pharmaceutical composition Substances 0.000 title description 4
150000003839 salts Chemical class 0.000 claims abstract description 12
241000124008 Mammalia Species 0.000 claims abstract description 6
150000001875 compounds Chemical class 0.000 claims abstract description 6
239000000825 pharmaceutical preparation Substances 0.000 claims description 8
206010012335 Dependence Diseases 0.000 claims description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
229940049706 benzodiazepine Drugs 0.000 claims description 2
229960003920 cocaine Drugs 0.000 claims description 2
229960002715 nicotine Drugs 0.000 claims description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 2
229960002695 phenobarbital Drugs 0.000 claims description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
238000000034 method Methods 0.000 abstract description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000003826 tablet Substances 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000203 mixture Substances 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
-1 hydrochloric Chemical class 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229960003660 sertraline hydrochloride Drugs 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical class C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
229940125709 anorectic agent Drugs 0.000 description 1
230000001539 anorectic effect Effects 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
229960002069 diamorphine Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Addiction (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
General Factory Administration (AREA)
Saccharide Compounds (AREA)

IL9547290A 1989-08-30 1990-08-23 A medicinal product containing sertraline for use in the treatment of chemical addictions IL95472A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US40064789A	1989-08-30	1989-08-30

Publications (1)

Publication Number	Publication Date
IL95472A true IL95472A (en)	1996-05-14

Family

ID=23584453

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9547290A IL95472A (en)	1989-08-30	1990-08-23	A medicinal product containing sertraline for use in the treatment of chemical addictions

Country Status (16)

Country	Link
EP (1)	EP0415612B1 (de)
JP (1)	JPH0393719A (de)
KR (1)	KR930000049B1 (de)
AT (1)	ATE96999T1 (de)
AU (1)	AU617622B2 (de)
CA (1)	CA2024181C (de)
DE (1)	DE69004529T2 (de)
DK (1)	DK0415612T3 (de)
HU (1)	HUT58513A (de)
IE (1)	IE63137B1 (de)
IL (1)	IL95472A (de)
MY (1)	MY106939A (de)
NZ (1)	NZ235100A (de)
PH (1)	PH27544A (de)
PT (1)	PT95118B (de)
ZA (1)	ZA906882B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE96999T1 (de) *	1989-08-30	1993-11-15	Pfizer	Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
BR9810739A (pt) *	1997-07-01	2000-09-12	Pfizer Productsd Inc	Composições de sertralina solubilizada
CA2290966C (en)	1997-07-01	2005-12-20	Pfizer Inc.	Sertraline salts and sustained-release dosage forms of sertraline
ES2209490T3 (es) *	1998-10-13	2004-06-16	Pfizer Products Inc.	Concentrado oral de sertralina.
US6727283B2 (en)	1998-10-13	2004-04-27	Pfizer Inc.	Sertraline oral concentrate
GB2392385A (en) *	2002-09-02	2004-03-03	Cipla Ltd	Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4536518A (en) *	1979-11-01	1985-08-20	Pfizer Inc.	Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4803076A (en) *	1986-09-04	1989-02-07	Pfizer Inc.	Controlled release device for an active substance
US4999382A (en) *	1988-10-26	1991-03-12	Massachusetts Institute Of Technology	Compositions for treating tobacco withdrawal symptoms and methods for their use
ATE96999T1 (de) *	1989-08-30	1993-11-15	Pfizer	Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
US4962128A (en) *	1989-11-02	1990-10-09	Pfizer Inc.	Method of treating anxiety-related disorders using sertraline

1990
- 1990-08-17 AT AT90309062T patent/ATE96999T1/de not_active IP Right Cessation
- 1990-08-17 DE DE90309062T patent/DE69004529T2/de not_active Expired - Fee Related
- 1990-08-17 DK DK90309062.9T patent/DK0415612T3/da active
- 1990-08-17 EP EP90309062A patent/EP0415612B1/de not_active Expired - Lifetime
- 1990-08-21 PH PH41055A patent/PH27544A/en unknown
- 1990-08-23 IL IL9547290A patent/IL95472A/en not_active IP Right Cessation
- 1990-08-28 PT PT95118A patent/PT95118B/pt not_active IP Right Cessation
- 1990-08-28 MY MYPI90001471A patent/MY106939A/en unknown
- 1990-08-28 CA CA002024181A patent/CA2024181C/en not_active Expired - Fee Related
- 1990-08-29 ZA ZA906882A patent/ZA906882B/xx unknown
- 1990-08-29 HU HU905683A patent/HUT58513A/hu unknown
- 1990-08-29 AU AU61943/90A patent/AU617622B2/en not_active Ceased
- 1990-08-29 IE IE312490A patent/IE63137B1/en not_active IP Right Cessation
- 1990-08-29 KR KR1019900013369A patent/KR930000049B1/ko not_active Expired - Fee Related
- 1990-08-30 NZ NZ235100A patent/NZ235100A/en unknown
- 1990-08-30 JP JP2229546A patent/JPH0393719A/ja active Pending

Also Published As

Publication number	Publication date
CA2024181C (en)	1994-11-08
KR910004188A (ko)	1991-03-28
ZA906882B (en)	1992-04-29
PT95118B (pt)	1997-05-28
MY106939A (en)	1995-08-30
HUT58513A (en)	1992-03-30
DE69004529D1 (de)	1993-12-16
AU617622B2 (en)	1991-11-28
PH27544A (en)	1993-08-18
DK0415612T3 (da)	1993-12-13
AU6194390A (en)	1991-04-18
DE69004529T2 (de)	1994-02-24
IE63137B1 (en)	1995-03-22
EP0415612B1 (de)	1993-11-10
NZ235100A (en)	1997-05-26
HU905683D0 (en)	1991-03-28
IE903124A1 (en)	1991-03-13
EP0415612A3 (en)	1992-02-19
KR930000049B1 (ko)	1993-01-06
EP0415612A2 (de)	1991-03-06
JPH0393719A (ja)	1991-04-18
PT95118A (pt)	1991-05-22
ATE96999T1 (de)	1993-11-15
CA2024181A1 (en)	1991-03-01

Legal Events

Date	Code	Title
1996-10-16	FF	Patent granted
1996-12-05	KB	Patent renewed
2000-11-21	KB	Patent renewed
2004-09-27	KB	Patent renewed
2009-09-15	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0429189B1 (de)	2002-01-23	Verwendung von Sertraline zur Herstellung eines Arzneimittels zur Behandlung von obsessiv-kompulsiven Erkrankungen
US4940731A (en)	1990-07-10	Method of treating premature ejaculation using sertraline
IE83452B1 (en)		Use of sertraline for the manufacture of a medicament for treating obsessive-compulsive disorders
CA1121726A (en)	1982-04-13	Drug for the treatment of the central nervous system
CZ290691B6 (cs)	2002-09-11	Farmaceutický prostředek
US5130338A (en)	1992-07-14	Method of treating chemical dependencies using sertraline
US5026716A (en)	1991-06-25	Method of treatment of anxiety and anxio-depressive disorders
IL95472A (en)	1996-05-14	A medicinal product containing sertraline for use in the treatment of chemical addictions
EP0768083B1 (de)	2003-03-26	Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
IE84561B1 (en)	2007-04-18	Use of sertraline to treat social phobia
IE83776B1 (en)	2005-01-26	Use of sertraline to treat post traumatic stress disorder
US5919828A (en)	1999-07-06	Racemic propranolol
MXPA96002793A (en)	1998-01-01	Use of sertraline to treat patients after an infection of miocar